{"prompt": "['Naloxone is a potent opioid antagonist at the -opioid receptor and precipitates opioid withdrawal when', 'administered parenterally in individuals physically dependent on full opioid agonists. Naloxone has', 'limited sublingual absorption such that the inclusion of naloxone in buprenorphine/naloxone reduces', 'the potential for parenteral abuse of buprenorphine (i.e. by crushing and dissolving tablets or dissolving', 'film for intravenous injection).', 'Buprenorphine/naloxone is available as both a sublingual film and a tablet.', 'Buprenorphine/naloxone sublingual film is supplied as an orange rectangular sublingual film with a white', 'printed logo in four dosage strengths:', 'buprenorphine/naloxone 2 mg/0.5 mg', 'buprenorphine/naloxone 4 mg/1 mg', 'buprenorphine/naloxone 8 mg/2 mg', 'buprenorphine/naloxone: 12 mg/3 mg', 'Buprenorphine/naloxone sublingual tablets are supplied in 2 dosage strengths:', 'buprenorphine/naloxone 2 mg/0.5 mg', 'buprenorphine/naloxone 8mg/2 mg', 'Typical maintenance doses range from 8-16 mg of buprenorphine with 2 to 4 mg of naloxone.', 'The safety of buprenorphine/naloxone is supported by clinical trials of buprenorphine (Subutex)', 'sublingual tablets and buprenorphine/naloxone sublingual tablets and buprenorphine/naloxone', 'sublingual solution and buprenorphine/naloxone sublingual tablets. In total, safety data from clinical', 'studies are available from over 3000 opioid-dependent subjects exposed to buprenorphine at doses in', 'the range used in the treatment of opioid dependence. The most common side effects of', 'buprenorphine/naloxone include dizziness, drowsiness, abdominal pain, nausea, constipation, headache,', 'insomnia, hyperhidrosis, and flushing. The sublingual film product may also cause numbness, burning,', 'tingling of the mouth.', 'Buprenorphine, particularly when taken by the IV route, in combination with benzodiazepines or other', 'central nervous system (CNS) depressants (including alcohol), has been associated with significant', 'respiratory depression and death. Many, but not all, post-marketing reports regarding coma and death', 'associated with the concomitant use of buprenorphine and benzodiazepines involved misuse by self-', 'injection. Deaths have also been reported in association with concomitant administration of', 'buprenorphine with other depressants such as alcohol or other CNS depressant drugs.', '3.4 Compliance', 'This study will be conducted in compliance with this protocol, Good Clinical Practice (GCP), and all', 'applicable regulatory requirements.', '4 OBJECTIVES', '4.1', 'Primary Objective:', 'To assess the effectiveness, as measured by SVR-12, of HCV treatment with Epclusa', 'administered by psychiatrist/licensed buprenorphine/naloxone providers during regularly', 'CRI 15-05 Protocol 13SEP2017', 'Page 17']['scheduled visits to an outpatient addiction clinic for buprenorphine/naloxone replacement', 'therapy and mental healthcare.', '4.2', 'Secondary Objectives:', 'To assess the impact of HCV treatment on health-related quality of life among subjects on', 'buprenorphine/naloxone therapy.', 'To assess adherence to Epclusa therapy in subjects administered treatment in the context of', 'visits to an outpatient addiction clinic for buprenorphine/naloxone replacement therapy and', 'mental healthcare.', '4.3', 'Exploratory Objective:', 'To design and assess a curriculum and mentorship program to support psychiatrists with', 'managing HCV infection. For the purpose of this study, the curriculum will be tailored to the', 'management of HCV genotypes 1, 2, 3, 4, 5 and 6 and treatment with Epclusa.', '5', 'STUDY DESIGN', '5.1 Treatment Plan and Regimen', 'This is a single arm pilot study of administering HCV treatment at an outpatient addiction clinic staffed by', 'psychiatrists at Cambridge Health Alliance. Approximately 20 subjects will be enrolled and treated with', 'Epclusa tablet once daily for 12 weeks.', '5.2 Subject Recruitment', 'Patients with HCV infection already engaged in addiction treatment at Cambridge Health Alliance will be', 'identified by members of the study team and/or the psychiatrist-buprenorphine/naloxone providers and', 'approached regarding participation. Importantly, HCV status will already be recorded in the medical', 'record as all patients are routinely screened for hepatitis C infection upon entry into the OAS program.', 'Psychiatrist-buprenorphine/naloxone prescribers will be approached by study investigators to', 'participate based on meeting the entry criteria as providers employed at the outpatient addiction clinic', 'at Cambridge Health Alliance.', '5.3 Visit Schedule', 'All study visits will take place at the outpatient addiction clinic at Cambridge Health Alliance. A study', 'coordinator employed by Community Research Initiative will conduct the study visits in conjunction with', 'the psychiatrist-buprenorphine/naloxone provider at Cambridge Health Alliance.', 'Subjects will complete all of the following visits: Screening, Baseline/Day 1, On-Treatment Visits', 'approximately biweekly throughout treatment, and Post-Treatment Visits at Weeks 4 and 12 (from time', 'of last dose of study drug.)', 'Screening assessments will be completed within 28 days of the Baseline/Day 1 Visit. The screening', 'window may be extended to 42 days prior to Day 1 for subjects with in extenuating circumstances, if', 'approved by Medical Monitor.', 'The assessments performed at each visit are described in Sections 8.2 and 8.3.', 'CRI 15-05 Protocol 13SEP2017', 'Page 18']\n\n###\n\n", "completion": "END"}